Tranexamic acid in paediatric cardiac surgery.

Area of Science:

• Pediatric Cardiac Surgery
• Cardiovascular Research
• Pharmacology

Background:

• Antifibrinolytic agents are standard in adult cardiac surgery to minimize blood loss.
• Limited research exists on newer agents like tranexamic acid in pediatric cardiac surgery.
• Cyanotic heart disease presents unique challenges in pediatric cardiac surgery.

Purpose of the Study:

• To evaluate the efficacy of tranexamic acid in reducing postoperative blood loss.
• To assess the impact of tranexamic acid on blood product usage in children with cyanotic heart disease.
• To investigate the effect of tranexamic acid on coagulation parameters post-cardiac surgery.

Main Methods:

• A randomized controlled trial involving 120 children with cyanotic heart disease.
• Two groups: control (no drug) and study (tranexamic acid 10 mg/kg at specific intervals).
• Measured mediastinal drainage, blood product use, and coagulation tests (ACT, fibrinogen, FDPs, platelets).

Main Results:

• Tranexamic acid group showed significantly lower blood loss and blood product requirements.
• Reduced rates of re-exploration were observed in the tranexamic acid group.
• Preserved fibrinogen levels and lower fibrin degradation products in the tranexamic acid group.

Conclusions:

• Tranexamic acid is highly effective in pediatric cardiac surgery for cyanotic heart disease.
• It significantly reduces postoperative bleeding and the need for transfusions.
• The study supports tranexamic acid use to improve surgical outcomes in this pediatric population.